AC Immune SA
NASDAQ:ACIU
AC Immune SA
Research & Development
AC Immune SA
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
AC Immune SA
NASDAQ:ACIU
|
Research & Development
-CHf61.6m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-14%
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Research & Development
-$284.8m
|
CAGR 3-Years
15%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-37%
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Research & Development
-CHf105.9m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-6%
|
|
|
Idorsia Ltd
SIX:IDIA
|
Research & Development
-CHf98.4m
|
CAGR 3-Years
37%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Research & Development
-CHf8.6m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
Research & Development
-CHf1.2m
|
CAGR 3-Years
62%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
AC Immune SA
Glance View
AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. The company is headquartered in Lausanne, Vaud and currently employs 143 full-time employees. The company went IPO on 2016-09-23. The firm focuses on precision medicine for neurodegenerative diseases. The company designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The firm's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. The company has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
See Also
What is AC Immune SA's Research & Development?
Research & Development
-61.6m
CHF
Based on the financial report for Sep 30, 2025, AC Immune SA's Research & Development amounts to -61.6m CHF.
What is AC Immune SA's Research & Development growth rate?
Research & Development CAGR 10Y
-14%
Over the last year, the Research & Development growth was 0%. The average annual Research & Development growth rates for AC Immune SA have been 2% over the past three years , -1% over the past five years , and -14% over the past ten years .
